Evidence map›Paper›PMID 28430830›Full record

ArticleJAMA2017

Assessment of Global Kidney Health Care Status.

Aminu K Bello, Adeera Levin, Marcello Tonelli, Ikechi G Okpechi, John Feehally, David Harris, Kailash Jindal, Babatunde L Salako, Ahmed Rateb, Mohamed A Osman and 6 more

3 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in JAMA, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 231 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
231citing papers in PubMed, 10 pooled it
27.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03588520 naunknown statusnot on this mapstarted 2018, after this paper: background citation

Investigation Of The Utility Of Home Blood Pressure Measurements Towards Improving The Management Of Hypertension In Patients In Stage 3 And 4 Chronic Kidney Disease

TypeinterventionalSponsorAristotle University Of ThessalonikiRan2018 to 2022Enrolled70ConditionsHypertension, Chronic Kidney DiseasesArmsHome Blood Pressure Monitoring
NCT03923933 phase2completednot on this mapstarted 2019, after this paper: background citation

Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial

TypeinterventionalSponsorHospital General de México Dr. Eduardo LiceagaRan2019 to 2019Enrolled34ConditionsRenal Insufficiency, ChronicArmsChlorthalidone, Bumetanide
NCT06654921 nanot yet recruitingnot on this mapstarted 2025, after this paper: background citation

The Safety and Efficacy of Remote Ischemic Conditioning for the Treatment of Diabetic Kidney Disease: a Single-center Double-blinded Randomized Controlled Study

TypeinterventionalSponsorCapital Medical UniversityRan2025 to 2025Enrolled60ConditionsDiabetic Kidney Disease (DKD)ArmsRemote ischemic conditioning, Sham remote ischemic conditioning, Standard medication therapy
3 · Its place in the literature

Who cites it

231 citing papers in PubMed, 10 syntheses or guidelines pooled it, 474 citations in OpenAlex.

  1. Pooled it
  2. Metformin for preventing the progression of chronic kidney disease.The Cochrane database of systematic reviews · 2024 · on this map
    Pooled it
  3. Home versus in-centre haemodialysis for people with kidney failure.The Cochrane database of systematic reviews · 2024
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Non-medical barriers reported by nephrologists when providing renal replacement therapy or comprehensive conservative management to end-stage kidney disease patients: a systematic review.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2021
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

171 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 5 countries.

Aminu K BelloDepartment of Medicine, University of Alberta, Edmonton, Canada.
Adeera LevinDivision of Nephrology, University of British Columbia, Vancouver, Canada.
Marcello TonelliDepartment of Medicine, University of Calgary, Calgary, Alberta, Canada4Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Ikechi G OkpechiDivision of Nephrology and Hypertension, University of Cape Town, Cape Town, South Africa.
John FeehallyUniversity Hospitals of Leicester, University of Leicester, Leicester, England.
David HarrisCentre for Transplantation and Renal Research, University of Sydney at Westmead Hospital, Sydney, Australia.
Kailash JindalDepartment of Medicine, University of Alberta, Edmonton, Canada.
Babatunde L SalakoDepartment of Medicine, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Ahmed RatebDepartment of Medicine, University of Alberta, Edmonton, Canada.
Mohamed A OsmanDepartment of Medicine, University of Alberta, Edmonton, Canada.
Bilal QarniDepartment of Medicine, University of Alberta, Edmonton, Canada.
Syed SaadDepartment of Medicine, University of Alberta, Edmonton, Canada.
Meaghan LunneyDepartment of Medicine, University of Calgary, Calgary, Alberta, Canada4Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Natasha WiebeDepartment of Medicine, University of Alberta, Edmonton, Canada.
Feng YeDepartment of Medicine, University of Alberta, Edmonton, Canada.
David W JohnsonCentre for Kidney Disease Research, University of Queensland at Princess Alexandra Hospital, Brisbane, Australia10Translational Research Institute, Brisbane, Australia11Metro South and Ipswich Nephrology and Transplant Services, Princess Alexandra Hospital, Brisbane, Australia.
University of Alberta · CAUniversity of Calgary · CATranslational Research Institute · AUUniversity Hospitals of Leicester NHS Trust · GBUniversity of British Columbia · CAUniversity of Cape Town · ZAUniversity of Ibadan · NGWestmead Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Kidney disease is a substantial worldwide clinical and public health problem, but information about available care is limited. Objective: To collect information on the current state of readiness, capacity, and competence for the delivery of kidney care across countries and regions of the world. Design, Setting, and Participants: Questionnaire survey administered from May to September 2016 by the International Society of Nephrology (ISN) to 130 ISN-affiliated countries with sampling of key stakeholders (national nephrology society leadership, policy makers, and patient organization representatives) identified by the country and regional nephrology leadership through the ISN. Main Outcomes and Measures: Core areas of country capacity and response for kidney care. Results: Responses were received from 125 of 130 countries (96%), including 289 of 337 individuals (85.8%, with a median of 2 respondents [interquartile range, 1-3]), representing an estimated 93% (6.8 billion) of the world's population of 7.3 billion. There was wide variation in country readiness, capacity, and response in terms of service delivery, financing, workforce, information systems, and leadership and governance. Overall, 119 (95%), 95 (76%), and 94 (75%) countries had facilities for hemodialysis, peritoneal dialysis, and kidney transplantation, respectively. In contrast, 33 (94%), 16 (45%), and 12 (34%) countries in Africa had facilities for hemodialysis, peritoneal dialysis, and kidney transplantation, respectively. For chronic kidney disease (CKD) monitoring in primary care, serum creatinine with estimated glomerular filtration rate and proteinuria measurements were reported as always available in only 21 (18%) and 9 (8%) countries, respectively. Hemodialysis, peritoneal dialysis, and transplantation services were funded publicly and free at the point of care delivery in 50 (42%), 48 (51%), and 46 (49%) countries, respectively. The number of nephrologists was variable and was low (<10 per million population) in Africa, the Middle East, South Asia, and Oceania and South East Asia (OSEA) regions. Health information system (renal registry) availability was limited, particularly for acute kidney injury (8 countries [7%]) and nondialysis CKD (9 countries [8%]). International acute kidney injury and CKD guidelines were reportedly accessible in 52 (45%) and 62 (52%) countries, respectively. There was relatively low capacity for clinical studies in developing nations. Conclusions and Relevance: This survey demonstrated significant interregional and intraregional variability in the current capacity for kidney care across the world, including important gaps in services and workforce. Assuming the responses accurately reflect the status of kidney care in the respondent countries, the findings may be useful to inform efforts to improve the quality of kidney care worldwide.

Indexed as

Developing CountriesHealth PolicyLeadershipRenal Insufficiency, ChronicAcute Kidney InjuryAfricaAsiaCapacity BuildingDelivery of Health CareHealth Information SystemsHumansMiddle EastNephrologyPolicy MakingPrimary Health CareRenal Dialysis

Identifiers

PMID28430830
PMCPMC5470418
OpenAlexW2606731302

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.